Abstract
Purpose
To investigate the impact of the AB0 and the Rhesus blood group system on outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).
Methods
We included 511 UCB patients treated with RC without neoadjuvant chemotherapy from 1996 to 2011 at our institution. Cox and logistic regression models assessed the association of the AB0 blood group antigen and Rhesus factor expression with tumor biologic features and outcomes, respectively.
Results
In total, 216 patients (42.3 %) had the blood group antigen A0, 73 patients (14.3 %) the antigen B0, 33 patients (6.4 %) the antigen AB and 189 patients (37.0 %) the antigen 00. In addition, 414 patients (81.0 %) were Rhesus factor positive. The AB0 blood group antigen expression was associated with a higher tumor grade (p = 0.003). In contrast, the Rhesus factor was not associated with any clinicopathologic characteristics. Neither the AB0 blood group antigens nor the Rhesus factor was associated with survival. In a sensitivity analysis of patients receiving adjuvant chemotherapy, however, the blood group antigen AB expression was associated with reduced cancer-specific and overall survival.
Conclusion
The AB0 blood group antigens and the Rhesus factor are not associated with survival. Although the AB0 blood groups and the Rhesus factor are analyzed in every patient treated with RC, they do not represent appropriate biomarkers for UCB outcome prognostication. The association of the AB0 blood group antigens with response to adjuvant chemotherapy requires further validation.
Similar content being viewed by others
References
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208
Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65(4):778–792. doi:10.1016/j.eururo.2013.11.046
Rink M, Lee DJ, Kent M, Xylinas E, Fritsche H-M, Babjuk M et al (2013) Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int 111(3b):E30–E36. doi:10.1111/j.1464-410X.2012.11433.x
Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G et al (2012) Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer 107(11):1826–1832
Rink M, Cha E, Green D, Hansen J, Robinson B, Lotan Y et al (2012) Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 13(2):122–135. doi:10.1007/s11934-012-0237-1
Kaffenberger SD, Morgan TM, Stratton KL, Boachie AM, Barocas DA, Chang SS et al (2012) ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int 110(11b):E641–E646. doi:10.1111/j.1464-410X.2012.11366.x
Rahbari N, Bork U, Hinz U, Leo A, Kirchberg J, Koch M et al (2012) AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer 12(1):319
Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bueno-de-Mesquita HB, Steplowski E et al (2010) Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 70(3):1015–1023. doi:10.1158/0008-5472.can-09-2993
Klatte T, Xylinas E, Rieken M, Kluth LA, Rouprêt M, Pycha A et al (2014) Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. J Urol 191(5):1238–1243. doi:10.1016/j.juro.2013.11.106
Süer E, Özcan C, Gökçe İ, Gülpınar Ö, Göğüş Ç, Türkölmez K et al (2014) Do blood groups have effect on prognosis of patients undergoing radical cystectomy? Int Urol Nephrol 46(8):1–6. doi:10.1007/s11255-014-0698-x
Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C et al (2014) Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. Urol Oncol Semin Orig Investig 32(5):625–630. doi:10.1016/j.urolonc.2013.11.010
Franchini M, Liumbruno GM (2013) ABO blood group: old dogma, new perspectives. Clin Chem Lab Med. doi:10.1515/cclm-2013-0168
Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O et al (2014) Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. Eur J Surg Oncol (EJSO). doi:10.1016/j.ejso.2014.03.003
Epstein JI, Amin MB, Reuter VR, Mostofi FK, Committee TBCC (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (Transitional Cell) neoplasms of the urinary bladder. Am J Surg Pathol 22(12):1435–1448
Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23(27):6533–6539. doi:10.1200/jco.2005.05.516
Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y et al (2010) Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 183(6):2165–2170. doi:10.1016/j.juro.2010.02.021
Bethesda MD (2012) Standards for blood banks and transfusion services. American Association of Blood Banks 28th edition
Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61(4):854–855. doi:10.1016/j.eururo.2011.12.055
Rafnar T, Sulem P, Thorleifsson G, Vermeulen SH, Helgason H, Saemundsdottir J et al (2014) Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Hum Mol Genet. doi:10.1093/hmg/ddu264
Malmström PU, Busch C, Norlen BJ, Andersson B (1988) Expression of ABH blood group isoantigen as a prognostic factor in transitional cell bladder carcinoma. Scand J Urol Nephrol 22(4):265–270
Freire-de-Lima L (2014) Sweet and sour: the impact of differential glycosylation in cancer cells undergoing epithelial-mesenchymal transition. Front Oncol. doi:10.3389/fonc.2014.00059
Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB (2010) ABO blood group and cancer. Eur J Cancer 46(18):3345–3350. doi:10.1016/j.ejca.2010.08.009
Wang JK, Boorjian SA, Frank I, Tarrell RF, Thapa P, Jacob EK et al (2014) Non-O Blood type is associated with an increased risk of venous thromboembolism after radical cystectomy. Urology 83(1):140–145. doi:10.1016/j.urology.2013.08.046
Primdahl H, von der Maase H, Sørensen F, Wolf H, Ørntoft T (2002) Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer. J Cancer Res Clin Oncol 128(6):295–301. doi:10.1007/s00432-002-0344-3
Caygill CP, Royston C, Charlett A, Wall CM, Gatenby PA, Ramus JR et al (2011) Barrett’s, blood groups and progression to oesophageal cancer: is nitric oxide the link? Eur J Gastroenterol Hepatol 23(9):801–806
Huang C-H, Ye M (2010) The Rh protein family: gene evolution, membrane biology, and disease association. Cell Mol Life Sci 67(8):1203–1218. doi:10.1007/s00018-009-0217-x
de Manzoni G, Verlato G, Di Leo A, Tasselli S, Bonfiglio M, Pedrazzani C et al (2001) Rhesus D-phenotype does not provide prognostic information additional to TNM staging in gastric cancer patients. Cancer Detect Prev 25(2):161–165
Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A, Kaplan B (2013) ABO blood groups are not associated with treatment response and prognosis in patients with local advanced non-small cell lung cancer. Asian Pac J Cancer Prev 14(6):3945–3948
Beckmann L (2008) Racial and ethnic distribution of ABO blood types. http://www.bloodbook.com/world-abo.html; Accessed 09/18/2014
Acknowledgments
Dr. Michael Rink is supported by the GEROK research Grant of the University of Hamburg.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical standard
The study was approved by the institutional review board and does not contain human studies.
Author information
Authors and Affiliations
Corresponding author
Additional information
Oliver Engel and Armin Soave have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Engel, O., Soave, A., Peine, S. et al. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. World J Urol 33, 1769–1776 (2015). https://doi.org/10.1007/s00345-015-1531-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-015-1531-6